Sysmex Corp
TSE:6869
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 166.8315
3 195
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sysmex Corp
Sysmex Corp
Net Issuance of Common Stock
Sysmex Corp
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sysmex Corp
TSE:6869
|
Net Issuance of Common Stock
-¥11.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Terumo Corp
TSE:4543
|
Net Issuance of Common Stock
-¥13.4B
|
CAGR 3-Years
-1 395%
|
CAGR 5-Years
-353%
|
CAGR 10-Years
-97%
|
|
|
Olympus Corp
TSE:7733
|
Net Issuance of Common Stock
-¥165B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-145%
|
|
|
Nihon Kohden Corp
TSE:6849
|
Net Issuance of Common Stock
-¥3.4B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-409%
|
CAGR 10-Years
N/A
|
|
|
JEOL Ltd
TSE:6951
|
Net Issuance of Common Stock
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fukuda Denshi Co Ltd
TSE:6960
|
Net Issuance of Common Stock
-¥11.2B
|
CAGR 3-Years
-2 141%
|
CAGR 5-Years
-462%
|
CAGR 10-Years
N/A
|
|
Sysmex Corp
Glance View
In the bustling world of healthcare diagnostics, Sysmex Corporation stands as a beacon of innovation and precision. Originating from the vibrant city of Kobe, Japan, the company has mastered the art of transforming complex scientific processes into streamlined solutions. With roots tracing back to the 1960s, Sysmex emerged as a pioneer in the field of hematology, developing technological marvels that analyze blood components with remarkable accuracy. This precision is not merely an academic pursuit; it translates into actionable insights for medical professionals, empowering them to diagnose and monitor conditions ranging from anemia to leukemia with a high degree of reliability. As the lifeblood of medical laboratories worldwide, Sysmex's automated analyzers and testing systems are indispensable tools in pathologies, enabling swift and accurate patient care. Sysmex's business model is a symphony of product innovation and service excellence. The company thrives by blending advanced technologies with an ever-expanding portfolio of diagnostic instruments and reagents, ensuring that their systems remain both state-of-the-art and user-friendly. Revenue generation for Sysmex is a harmonious balance between instrument sales and the recurring income stream from consumables and after-sales service contracts. This dual approach not only secures initial capital from equipment sales but also ensures sustained engagement with their clients. By investing heavily in research and development, Sysmex continuously pushes the envelope in medical diagnostics, tapping into emerging fields like oncology, hemostasis, and urinalysis. In doing so, it fortifies its position as a global leader, committed to advancing healthcare outcomes through technological innovation and customer-centric practices.
See Also
What is Sysmex Corp's Net Issuance of Common Stock?
Net Issuance of Common Stock
-11.7B
JPY
Based on the financial report for Sep 30, 2024, Sysmex Corp's Net Issuance of Common Stock amounts to -11.7B JPY.
You don't have any saved screeners yet
